Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025.
Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of its research in respiratory and emerging infectious diseases.
COVID-19
Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants - Oral Presentation
Presenter: Frances Priddy
Session: Advances in vaccine effectiveness for viral respiratory infections
Date: April 12 | Time & Location: 11:00 (Hall 9)Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses - Oral Presentation
Presenter: Spyros Chalkias
Session: Vaccines and prophylaxis against respiratory viral infections
Date: April 13 | Time & Location: 11:00 (Hall 9)Clinical evaluation of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine - Poster Presentation
Presenter: Spyros Chalkias
Session: COVID-19
Date: April 12 | Time & Location: 12:00 (Poster Hall)Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged ≥12 years - Poster Presentation
Presenter: Christina Grassi
Session: COVID-19
Date: April 12 | Time & Location: 12:00 (Poster Hall)
RSV
Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years - E-Poster Presentation
Presenter: Mihir Desai
Session: On the frontiers of vaccine-driven prevention
Date: April 12 | Time & Location: 08:30 (Arena 1)Safety and immunogenicity of mRNA-1345 revaccination at 24 months in adults ≥60 years - Poster Presentation
Presenter: Mihir Desai
Session: Clinical Trials
Date: April 15 | Time & Location: 12:00 (Poster Hall)Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States - Poster Presentation
Presenter: Clarisse Demont
Session: Influenza and respiratory viruses
Date: April 12 | Time & Location: 12:00 (Poster Hall)Association of virology swab positivity in adults aged ≥40 years with Computerized Medical Record Reported Acute Respiratory Infection (ARI) Subgroups: Observational Study of ARI (ObservatARI) - Poster Presentation
Presenter: Simon De Lusignan
Session: Influenza and respiratory viruses
Date: April 12 | Time & Location: 12:00 (Poster Hall)
Mpox
Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial - Oral Presentation
Presenter: Hiwot Hiruy
Session: Novel vaccines in clinical development
Date: April 14 | Time & Location: 17:30 (Hall 3)
Cytomegalovirus
Long-term safety and immunogenicity of cytomegalovirus mRNA-1647 vaccine in healthy adults: 36-month results from a phase 2 extension trial - Poster Presentation
Presenter: Ben Lorenz
Session: Clinical Trials
Date: April 15 | Time & Location: 12:00 (Poster Hall)
Influenza
Six-month persistence and safety of mRNA-based influenza or multicomponent influenza/COVID-19 vaccines versus licensed comparators in adults aged ≥18 years - Poster Presentation
Presenter: Mieke Soens
Session: Influenza and respiratory viruses
Date: April 12 | Time & Location: 12:00 (Poster Hall)
Norovirus
Incidence and severity of sporadic, medically attended norovirus infection in the United States, 2023-2024 - Poster Presentation
Presenter: Mark A. Schmidt
Session: Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology
Date: April 12 | Time & Location: 12:00 (Poster Hall)
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for Moderna's vaccine candidates to alleviate disease outcomes. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.Mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna Inc.
View the original press release on ACCESS Newswire
ModernaTX, Inc
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Announcing Zion Shores17.4.2025 22:15:00 CEST | Press release
A First for Utah: Ride Waves, Live Local, and Discover Adventure-Driven Lifestyle WASHINGTON, UT / ACCESS Newswire / April 17, 2025 / Alaia Development and Desert Lakes LLC are thrilled to announce ZION SHORES - a world class inland surf destination in Washington, Utah. ZION SHORES will be the centerpiece of the Alaia's Master planned community, formerly known as Stucki Farms. After years of water research, engineering, and collaboration with the city of Washington, we have reached an agreement and are moving forward on a monumental project in the heart of southern Utah. This will truly be unlike any other surf and recreation area in the world. Water is a precious resource, especially in Southern Utah, and ZION SHORES was conceived and designed with the vision of protecting that resource. Our surf lagoons will be filled with non-potable brackish water not suitable for drinking or irrigation from privately owned onsite wells. Brackish water is much too costly to convert into culinary or
PerfectSwell(R) Zion To Start Construction17.4.2025 13:05:00 CEST | Press release
Generation 6 Technology Set for Southern Utah SOLANA BEACH, CA / ACCESS Newswire / April 17, 2025 / American Wave Machines, the global leader in world-class surf pool destinations, announces a new project, PerfectSwell® Zion, a mixed-use development in Washington, Utah, the outdoor activity hub adjacent to Zion National Park. AWM is partnering with Desert Lakes LLC on the project. The commercial surf park anchors a luxury residential community called Zion Shores offering waterfront single family homes and beachfront townhouses. PerfectSwell® Zion will be open to the public with Zion Shores residents enjoying unique perks and surf priority. PerfectSwell® Zion opens in Q1 2027. Capping four years of in-house R&D, the project will feature Generation 6 PerfectSwell® surf technology bringing bigger, better waves, improved efficiency, cutting-edge sustainability features, and AWM's most innovative wave package yet. Gen 6 features optimization diagnostics utilizing historic and real time data
Camino and Nittetsu Complete Acquisition of Permitted Puquios Copper Project in Chile17.4.2025 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ( "Camino" or the "Company" ) is pleased to announce the completion of its previously announced 1 acquisition (the " Acquisition ") of all of the issued and outstanding shares of Cuprum Resources Chile SpA (" Cuprum "), which owns the construction-ready Puquios copper project located in Chile (the " Puquios Project "). "Camino is building a copper production platform, and Puquios is the right sized, long life, copper asset with primary permits in place to be the next copper mine in the world's largest copper jurisdiction 2 , Chile. The recent PFS demonstrates a project with an after-tax internal rate of return of 23.4% and a low capital cost of US$142M (see the Company's news release of March 17, 2025). Our next steps are to market our business plan to global capital markets to earn a re-rating as a near-term new copper producer in the sector. We are pleased that our 50% JV partner
OMP Positioned Highest for Ability to Execute in the 2025 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions17.4.2025 11:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / April 17, 2025 / OMP, a global leader in supply chain planning solutions, has been named a Leader in the Gartner Magic Quadrant for the 10th consecutive time. Positioned highest for 'Ability to Execute,' OMP believes this recognition underscores its consistent delivery of innovative solutions and measurable business results to global supply chains. A proven platform for the most complex planning needs OMP attributes its continued advancement to the strength of Unison Planning™, a proven platform for all supply chain planning needs - from strategic to operational, and from demand to supply. As an open, cloud-native, and AI-driven platform, Unison Planning is designed to meet the evolving demand of dynamic global supply chains. It empowers businesses to make smarter, faster decisions and collaborate more effectively across complex networks. "Today's supply chain leaders must make decisions at the speed of business to stay competitive. It's the only way t
GA-ASI Announces Technology Investments From Blue Magic Netherlands16.4.2025 19:00:00 CEST | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 16, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is pleased to announce two businesses that it will invest in from the inaugural Blue Magic Netherlands (BMN) event last November: Emergent Swarm Solutions and Saluqi Motors. "The technologies presented by Emergent and Saluqi really stood out to us, and we're proud to be working with them," said Brad Lunn, managing director for GA-ASI. "I expect several other companies from the Blue Magic Netherlands event to emerge and we hope to make additional announcements in the near future." At the Blue Magic investment and innovation conference in the Netherlands, GA-ASI and its partners heard pitches from innovative Dutch companies about the important technologies they are developing. The event was organized collaboratively between GA-ASI, the Dutch Ministry of Defense, the Dutch Ministry of Economic Affairs, Brainport Development in Eindhoven, and Brabant Development Agency (BOM). The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom